Westerman B A, Breuer R H J, Poutsma A, Chhatta A, Noorduyn L A, Koolen M G J, Postmus P E, Blankenstein M A, Oudejans C B M
Department of Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands.
Int J Biol Markers. 2007 Apr-Jun;22(2):114-23. doi: 10.1177/172460080702200205.
Microarray-based expression profiling studies of lung adenocarcinomas have defined neuroendocrine subclasses with poor prognosis. As neuroendocrine development is regulated by members of the achaete-scute and atonal classes of basic helix-loop-helix (bHLH) transcription factors, we analyzed lung tumors for expression of these factors. Out of 13 bHLH genes tested, 4 genes, i.e., achaete-scute complex-like 1 (ASCL1, HASH1, Mash1), atonal homolog 1 (ATOH1, HATH1, MATH1), NEUROD4 (ATH-3, Atoh3, MATH-3) and neurogenic differentiation factor 1 (NEUROD1, NEUROD, BETA2), showed differential expression among lung tumors and absent or low expression in normal lung. As expected, tumors that have high levels of ASCL1 also express neuroendocrine markers, and we found that this is accompanied by increased levels of NEUROD1. In addition, we found ATOH1 expression in 9 (16%) out of 56 analyzed adenocarcinomas and these tumors showed neuroendocrine features as shown by dopa decarboxylase mRNA expression and immunostaining for neuroendocrine markers. ATOH1 expression as well as NEUROD4 was observed in small cell lung carcinoma (SCLC), a known neuroendocrine tumor. Since ATOH1 is not known to be involved in normal lung development, our results suggest that aberrant activation of ATOH1 leads to a neuroendocrine phenotype similar to what is observed for ASCL1 activation during normal neuroendocrine development and in lung malignancies. Our preliminary data indicate that patients with ATOH1-expressing adenocarcinomas might have a worse prognosis.
基于微阵列的肺腺癌表达谱研究已确定了预后较差的神经内分泌亚类。由于神经内分泌发育受碱性螺旋-环-螺旋(bHLH)转录因子的achaete-scute和atonal类成员调控,我们分析了肺肿瘤中这些因子的表达。在所检测的13个bHLH基因中,有4个基因,即achaete-scute复合体样1(ASCL1、HASH1、Mash1)、atonal同源物1(ATOH1、HATH1、MATH1)、NEUROD4(ATH-3、Atoh3、MATH-3)和神经源性分化因子1(NEUROD1、NEUROD、BETA2),在肺肿瘤中表现出差异表达,而在正常肺组织中表达缺失或水平较低。正如预期的那样,ASCL1水平高的肿瘤也表达神经内分泌标志物,并且我们发现这伴随着NEUROD1水平的升高。此外,我们在56例分析的腺癌中有9例(16%)检测到ATOH1表达,这些肿瘤表现出神经内分泌特征,如多巴脱羧酶mRNA表达以及神经内分泌标志物免疫染色所示。在已知的神经内分泌肿瘤小细胞肺癌(SCLC)中观察到了ATOH1表达以及NEUROD4表达。由于ATOH1不参与正常肺发育,我们的结果表明,ATOH1的异常激活导致了一种神经内分泌表型,类似于在正常神经内分泌发育和肺恶性肿瘤中观察到的ASCL1激活所导致的表型。我们的初步数据表明,表达ATOH1的腺癌患者预后可能较差。